全文获取类型
收费全文 | 3679篇 |
免费 | 407篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 111篇 |
妇产科学 | 106篇 |
基础医学 | 572篇 |
口腔科学 | 94篇 |
临床医学 | 538篇 |
内科学 | 701篇 |
皮肤病学 | 57篇 |
神经病学 | 213篇 |
特种医学 | 370篇 |
外科学 | 448篇 |
综合类 | 69篇 |
预防医学 | 230篇 |
眼科学 | 52篇 |
药学 | 293篇 |
中国医学 | 11篇 |
肿瘤学 | 212篇 |
出版年
2023年 | 22篇 |
2021年 | 47篇 |
2020年 | 24篇 |
2019年 | 46篇 |
2018年 | 75篇 |
2017年 | 36篇 |
2016年 | 48篇 |
2015年 | 71篇 |
2014年 | 102篇 |
2013年 | 108篇 |
2012年 | 113篇 |
2011年 | 161篇 |
2010年 | 97篇 |
2009年 | 119篇 |
2008年 | 157篇 |
2007年 | 110篇 |
2006年 | 129篇 |
2005年 | 137篇 |
2004年 | 124篇 |
2003年 | 127篇 |
2002年 | 106篇 |
2001年 | 107篇 |
2000年 | 102篇 |
1999年 | 106篇 |
1998年 | 84篇 |
1997年 | 76篇 |
1996年 | 95篇 |
1995年 | 88篇 |
1994年 | 66篇 |
1993年 | 74篇 |
1992年 | 79篇 |
1991年 | 85篇 |
1990年 | 81篇 |
1989年 | 99篇 |
1988年 | 106篇 |
1987年 | 95篇 |
1986年 | 88篇 |
1985年 | 83篇 |
1984年 | 70篇 |
1983年 | 47篇 |
1982年 | 54篇 |
1981年 | 36篇 |
1980年 | 30篇 |
1979年 | 40篇 |
1978年 | 25篇 |
1977年 | 32篇 |
1976年 | 33篇 |
1975年 | 33篇 |
1972年 | 22篇 |
1971年 | 20篇 |
排序方式: 共有4098条查询结果,搜索用时 31 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
In brain regions containing noradrenergic (NA) cell bodies or terminals, DSP-4 induces changes in the activity of catecholamine-synthesizing enzymes which suggest that central NA neurons are lesioned by this neurotoxin. In contrast, the lack of change in the same enzymatic activities in an area containing mostly adrenergic (A) neurons (C2 region), favors the hypothesis of a resistance of the A neurons to DSP-4. Furthermore, the enzymatic changes observed in peripheral organs suggest a peripheral activation of the NA cell bodies in response to lesioning of the sympathetic terminals by DSP-4. 相似文献
3.
The behavioral effects of the antidepressants nomifensine, diclofensine, bupropion, and imipramine were examined using a cocaine substitution drug self-administration procedure in baboons and a cocaine drug discrimination procedure in rats. Intravenous self-administration of the antidepressants was examined in baboons under conditions in which baseline responding was maintained by intravenous injections of cocaine HCl (0.32 mg/kg/injection). Drug was available under a fixed-ratio 80-response or 160-response schedule of intravenous injection. Each drug injection was followed by a 3-h time-out allowing a maximum of eight injections per day. The antidepressants or their vehicles were substituted for cocaine for a period of 15 days, followed by a return to the cocaine baseline. Nomifensine, diclofensine, and bupropion all maintained self-administration behavior at levels above those maintained by their respective vehicles. Some doses of nomifensine, diclofensine, and bupropion maintained levels of behavior similar to those maintained under baseline cocaine conditions. High doses of imipramine maintained levels of behavior above those maintained by its vehicle, but the amount of behavior maintained under these conditions was extremely small. In a second experiment rats were trained to discriminate 32 µmol/kg cocaine (IP 10 min presession) from no drug in a two-lever food reinforced drug discrimination procedure in which responding on one lever was reinforced following ten consecutive responses when the session was preceded by cocaine administration, while responding on the other lever was similarly reinforced in the absence of cocaine pretreatment. Cocaine, nomifensine, diclofensine, and bupropion all dose-dependently occasioned cocaine-appropriate responding. Imipramine did not occasion cocaine-appropriate responding over a range of behaviorally active doses. 相似文献
4.
T Ichikawa J C Lamb P I Christensson B Hartley-Asp J T Isaacs 《Cancer research》1992,52(11):3022-3028
Linomide (N-phenylmethyl-1,2-dihydro-4-hydroxyl-1-methyl-2-oxo-quinoline-3- carboxamide) is a quinoline 3-carboxamide which previously has been demonstrated to produce immunomodulator and antitumor effects when given in vivo. To test the possible antitumor effects of linomide against prostatic cancers, rats bearing five distinct Dunning R-3327 rat prostatic cancer sublines were treated daily with i.p. injections of linomide. These studies demonstrated that linomide has a reproducible antitumor effect against all of the prostatic cancers tested regardless of their growth rate, degree of morphologic differentiation, metastatic ability, or androgen responsiveness. This antitumor effect is observed only in vivo, not in vitro, and involves a cytotoxic response of the prostatic cancer cells. This cytotoxic response results in the retardation of the growth rate (i.e., increased tumor volume doubling time) of primary prostatic cancers and in metastatic lesions. Linomide's growth retardation is reversible, and thus continuous daily treatment with linomide is required for maximal antitumor response. Pretreatment of rats with linomide before tumor inoculation has no effect in addition to that produced by initiating linomide treatment at the time of tumor inoculation. No enhancement of either natural killer cell number or natural killer cell cytotoxic activity is induced by linomide treatment in the tumor-bearing rats. In addition, depletion of natural killer cell activity via injections of asialo-GM1 antiserum does not prevent the antitumor effects of linomide in vivo. Likewise, the antitumor effects of linomide are also produced in prostatic cancer-bearing athymic nude rats. These results suggest that the requirement for host involvement in the antitumor effects of linomide against rat prostatic cancers may involve both immune and nonimmune host mechanism(s) (e.g., antiangiogenesis). 相似文献
5.
6.
7.
8.
9.
10.